President Donald Trump has announced an MFN pricing deal with Regeneron to lower prescription drug prices that Americans pay for some of the world's most innovative drugs, in line with the lowest prices paid by other developed nations, known as the most-favored-nation, or MFN, price.
The agreement will provide every State Medicaid program in the country access to MFN drug prices on new Regeneron products, resulting in hundreds of millions in savings.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Joji Xavier
For comments and feedback: contact editorial@rttnews.com